We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) closed the most recent trading day at $142.55, moving +0.25% from the previous trading session. This change lagged the S&P 500's 0.63% gain on the day. Meanwhile, the Dow gained 0.68%, and the Nasdaq, a tech-heavy index, added 0.64%.
Prior to today's trading, shares of the world's biggest maker of health care products had gained 2.02% over the past month. This has outpaced the Medical sector's loss of 3.98% and the S&P 500's loss of 4.95% in that time.
JNJ will be looking to display strength as it nears its next earnings release, which is expected to be January 22, 2019. The company is expected to report EPS of $1.95, up 12.07% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $20.11 billion, down 0.42% from the prior-year quarter.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $8.16 per share and revenue of $81.32 billion. These results would represent year-over-year changes of +11.78% and +6.37%, respectively.
Investors should also note any recent changes to analyst estimates for JNJ. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.29% higher. JNJ is holding a Zacks Rank of #2 (Buy) right now.
Looking at its valuation, JNJ is holding a Forward P/E ratio of 17.42. This represents a premium compared to its industry's average Forward P/E of 14.5.
Investors should also note that JNJ has a PEG ratio of 2.22 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.98 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 69, putting it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
Johnson & Johnson (JNJ - Free Report) closed the most recent trading day at $142.55, moving +0.25% from the previous trading session. This change lagged the S&P 500's 0.63% gain on the day. Meanwhile, the Dow gained 0.68%, and the Nasdaq, a tech-heavy index, added 0.64%.
Prior to today's trading, shares of the world's biggest maker of health care products had gained 2.02% over the past month. This has outpaced the Medical sector's loss of 3.98% and the S&P 500's loss of 4.95% in that time.
JNJ will be looking to display strength as it nears its next earnings release, which is expected to be January 22, 2019. The company is expected to report EPS of $1.95, up 12.07% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $20.11 billion, down 0.42% from the prior-year quarter.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $8.16 per share and revenue of $81.32 billion. These results would represent year-over-year changes of +11.78% and +6.37%, respectively.
Investors should also note any recent changes to analyst estimates for JNJ. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.29% higher. JNJ is holding a Zacks Rank of #2 (Buy) right now.
Looking at its valuation, JNJ is holding a Forward P/E ratio of 17.42. This represents a premium compared to its industry's average Forward P/E of 14.5.
Investors should also note that JNJ has a PEG ratio of 2.22 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.98 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 69, putting it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.